Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene
Martin, Marie ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Consultation Génétique
SAUTOIS, Brieuc ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
Language :
English
Title :
Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene
Kimble, D.C., Lach, F.P., Gregg, S.Q., Donovan, F.X., Flynn, E.K., Kamat, A., et al. A comprehensive approach to identification of pathogenic FANCA variants in Fanconi anemia patients and their families. Hum Mutat 39 (2018), 237–254, 10.1002/humu.23366.
Wang, A.T., Smogorzewska, A., SnapShot: Fanconi anemia and associated proteins. Cell, 160(354–354), 2015, e1, 10.1016/j.cell.2014.12.031.
Neveling, K., Endt, D., Hoehn, H., Schindler, D., Genotype-phenotype correlations in Fanconi anemia. Mutat Res 668 (2009), 73–91, 10.1016/j.mrfmmm.2009.05.006.
Kutler, D.I., Auerbach, A.D., Satagopan, J., Giampietro, P.F., Batish, S.D., Huvos, A.G., et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol - Head Neck Surg 129 (2003), 106–112, 10.1001/archotol.129.1.106.
Kutler, D.I., Patel, K.R., Auerbach, A.D., Kennedy, J., Lach, F.P., Sanborn, E., et al. Natural history and management of Fanconi anemia patients with head and neck cancer: A 10-year follow-up. Laryngoscope 126 (2016), 870–879, 10.1002/lary.25726.
Tan, I., Cutcutache, I., Zang, Z., Iqbal, J., Yap, S., Hwang, W., et al. Fanconi ’ s Anemia in Adulthood : Chemoradiation-induced bone marrow failure and a novel FANCA mutation identified by targeted deep sequencing. J Clin Oncol 29 (2011), 591–594.
Adelstein, D.J., Li, Y., Adams, G.L., Wagner, H., Kish, J.A., Ensley, J.F., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003), 92–98, 10.1200/JCO.2003.01.008.
Hess, J., Unger, K., Orth, M., Schötz, U., Schüttrumpf, L., Zangen, V., et al. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance. Cancer Lett 386 (2017), 87–99, 10.1016/j.canlet.2016.11.014.
Kachnic, L.A., Li, L., Fournier, L., Willers, H., Fanconi Anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett 292 (2010), 73–79, 10.1016/j.canlet.2009.11.009.
Beltran, H., Eng, K., Mosquera, J.M., Sigaras, A., Romanel, A., Rennert, H., et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol 1 (2015), 466–474, 10.1001/jamaoncol.2015.1313.
De, K.SRM., Brink, A., Van Der Meulen, I.H., De Menezes, R.X., Te Beest, D.E., Leemans, C.R., et al. The FA/BRCA Pathway identified as the major predictor of cisplatin response in head and neck cancer by functional genomics. Mol Cancer Ther 16 (2017), 540–550, 10.1158/1535-7163.MCT-16-0457.
Wong, W.M., Parvathaneni, U., Jewell, P.D., Martins, R.G., Futran, N.D., Laramore, G.E., et al. Squamous cell carcinoma of the oral tongue in a patient with Fanconi anemia treated with radiotherapy and concurrent cetuximab: A case report and review of the literature. Head Neck 35 (2013), E292–E298, 10.1002/hed.23155.
Beckham, T.H., Leeman, J., Jillian Tsai, C., Riaz, N., Sherman, E., Singh, B., et al. Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature. Head Neck 41 (2019), 1418–1426, 10.1002/hed.25577.
